KW can't even explain the tech clearly. If the tech is so good and has great value
It has very little value.
No control arm in the ad hoc Lohr studies which proves the presence of CIABs does anything with Metronomic Ifosfamide.
Metronomic Ifosfamide itself overall survival in one study (1988) of 1st line patients was 3 months. Several tries in 2nd line patients about the same.
The next generation of Ifosfamide or Glufosfamide also failed in 1st line patients. Despite it's advantage of 1/4 the toxicity of Ifosfamide, and having active transport into the cell, rather than by passive diffusion. Glufosfamide is now in Phase 3 testing for 2nd line patients. Might end up as a palliative treatment in 2nd line. Relieve the tumor burden for a short period of time, making the patient feel better. Overall the aklylating agents just don't work that well in solid tumors.
Meanwhile Kenny has been pumping it as a promising cure. Implying it will do what the previously used first line drugs could not do.
News 
Market Data 
Discover 
AI
